New Cytometry Technique for Characterizing Viral Vectors
Kite Pharma, a Gilead Company, has developed a technique for analyzing individual lentiviral vector particles, which it hopes will allow better characterization of future in vivo CAR T therapy products than traditional Western blotting.
“The virus is going to be our product, and we want to have the deepest understanding we can have of that,” explains Kristen Kellar, a scientist working in analytical development at Kite.
“Given how new and nascent thein vivolentiviral vector delivery space is, we’re trying to understand what the methods are by which we can more robustly characterize our products,” adds Priti Hegde, PhD, senior vice president of research and development, also at Kite.
According to Kellar, the new technique will be of interest to everyone in gene and cell therapies based on enveloped viruses like lentiviruses. “As reagents are developed,” she says, “more people will be on board with how powerful this technology can be.”
The new technique is based on flow virometry and involves individual particles passing a detector where attributes, such as their size and proteins on the surface, can be characterized, she says.
This allows for, as an example, the mapping of protein distribution as differences in protein abundance between particles are not lost during averaging. As Kellar explains, if one vector particle has, for example, 10 times more of a specific protein than another, a Western blot would characterize both particles as the average of five times for both particles.
According to Kellar, while flow virometrry has been used in the past, new instruments focused on analysis of nanoparticles allow for deeper characterization.
“They’ve brought the technology to a place where we feel very confident that we’re seeing all the particles and they seem the right size,” she says. “What’s relatively new is we’re able to stain the protein on the surface, and there’s one abundant protein we can see.”
Going forward, Kite Pharma hopes to use the technology throughout the development process, including during the final stages to assess the consistency from batch-to-batch. They’re also investigating some quantitation bead sets, which will allow them to quantify viral proteins on the vector surface, she says.
Hegde adds, “Given how nascent the field [ofin vivocell therapy] is, what’s exciting for us is we’re already seeing clinical proof of concept and, so, the next challenge at Kite is knowing how to scale robustly.”
InsightsCell therapyFlow cytometryViral vector (Applied microbiology)Western blotting (Molecular tests)Gilead SciencesKite PharmaPrevious article
Extracellular Secretion System Could Solve Industry Endonuclease Production ChallengesNext article
MyotisBat Genomes Reveal How They Fight Viruses, Cancer, and Cellular DamageAlso of Interest
CAR T Manufacturing in Japan Gets Boost from Teijin-Shinshu University Research CollaborationTop 10 Contract Development and Manufacturing Organizations 202610 CDMO Up & Comers 2026AI Accelerates Biomanufacturing from Discovery to TranslationNo One-Size-Fits-All Solution for Autologous Cell Therapy ManufacturingDesign for Commercial Scale from Day OneRelated Media
EnablingIn VivoLentiviral Therapies: Manufacturing Strategies to Improve Purity, Scalability, and Clinical ReadinessSmart Vector Design for Improved Cell and Gene TherapiesFrom Functional Genomics to Cell Therapy: The Role of CRISPR-Based Gene EditingPrecision Base Editing Meets Single-Cell Multiomics to Advance Cell and Gene TherapiesASGCT 2024: A Video Update from BaltimoreGlobal Single-Use Network Support Assurance of SupplyTop 5ResourcesRecommended For YouPodcast
Touching Base
Touching Base is the dynamic podcast series from the editors ofGEN. Each episode features a rotating case of senior editors—including John Sterling, Kevin Davies, Julianna LeMieux, Alex Phillippidis, Uduak Thomas, Corinna Singleman, and Fay Lin—who delve into emerging stories, exchange ideas, and debate the latest trends in biotech. Additionally, they talk to some of the leading voices in the industry about what's now and next.Start listening today!
Stay up to date with the lasted episodes of Touching Base bysubscribing to theGENPodcast Newsletter
